Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$181.21
▲ $7.96 (+4.6%)
Market data updated: 09/17 12:11 AM
Fundamentals updated: 09/16/2026
News analyzed: 09/17/2026
Market Cap
Not available
Day Range
$175.37 - $182.19
52-Week Range
$140.08 - $246.33
Beta
—
Next Earnings
26.10.2026
UHS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-2.8% (1Y)
Strengths: 12/31 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 37.3%
Growth
Biggest negative driver
Operating margin stability
Operating margin is eroding over time
Quality
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
60
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
62
Quality
42
Value
55
Momentum
69
Risk
42
Sentiment
56
Fundamental
65
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
SCANNING UHS...
Recent media coverage on Universal Health Services focuses on its stock performance and investor updates. Following a post-earnings stock rise of 5.7 percent, reports highlighted
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Universal Health Services. News trend score: 56. Reason: 5 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
28
🎯 Conviction (vs. Emotion)
36
Psychology
97
Fundamentals
65
Technical
69
Valuation
55
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+28%
Market Narrative
52
Fundamental Reality
36
Narrative Gap
+16
🧠 StockIQ Psychologist
Market behavior suggests a **mixed but cautiously optimistic** stance, with **euphoria** and **FOMO** as dominant but tempered by weak momentum. The stock’s premium to fair value (+2% DCF) and 200-day average (+5.3%) contrasts with its stagnant price momentum (-1.0% ROC), indicating potential overvaluation bias. The narrative gap (11 points) hints at a disconnect between market expectations and fundamentals. The key question: *Will sentiment sustain the premium, or will momentum finally break negative?*
Updated: 09/08/2026, 09:46 PM
What could change this?
👥 What the crowd believes
"Universal Health Services stock has pulled ahead over the past three years, yet its current valuation checks still suggest the shares may be pricing in less optimism than the recent performance implies."
"Universal Health Services is deeply undervalued at 7.4x 2026E NTM earnings despite robust free cash flow and pricing power."
"The completed $835m acquisition of Talkspace can support investor expectations for a broader behavioral health offering. However, integration and execution risk..."
📈 5D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 81/100
🔴 Weakest match
Samuel Armstrong Nelson — 6/100
🗣️ Why do they disagree?
The methodologies for UHS split sharply between bullish and bearish camps, reflecting starkly different priorities. Optimists like **Charles Mackay** (81) and **Peter Lynch** (77) see little crowd-driven hype or undervaluation, while **Thorstein Veblen** (71) and **Samuel Armstrong Nelson** (68) highlight growth alignment and cyclical oversold conditions—suggesting structural tailwinds. Yet even these positive signals are tempered by **Howard Marks** (62) and **Edgar Lawrence Smith** (61), who caution that high expectations or lack of clarity may limit upside. On the other end, **Jesse Livermore** (38) and **Jack Schwager** (17) dismiss the stock outright, with Livermore’s trend-following rule and Schwager’s lack-of-setup discipline overriding any other factors. Meanwhile, **Philip Fisher** (21) and **Morgan Housel** (30) reject it for either failing quality/growth benchmarks or introducing volatility that erodes patience—showing how divergent definitions of risk, momentum, and long-term potential create such a wide spectrum of verdicts.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 81
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 77
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 71
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 68
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 67
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 61
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 54
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 46
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 45
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 42
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 42
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 38
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 28
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 21
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 8
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 6
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 278 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (7 bullish · 3 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
11.5%
Net Margin
8.6%
EBITDA Margin
15.0%
ROE
20.5%
ROA
9.6%
ROIC
—
EPS
$23.42
Cash
$137.80M
Total Debt
$4.75B
Current Ratio
1.05
Debt/Equity
0.65
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 1.9.2026 | $0.200 |
| 8.6.2026 | $0.200 |
| 7.6.2026 | $0.200 |
| 2.3.2026 | $0.200 |
| 1.3.2026 | $0.200 |
| 1.12.2025 | $0.200 |
| 30.11.2025 | $0.200 |
| 2.9.2025 | $0.200 |
| 1.9.2025 | $0.200 |
| 2.6.2025 | $0.200 |
| 1.6.2025 | $0.200 |
| 3.3.2025 | $0.200 |
How is Fair Value calculated? →
Current Price
$181.21
Estimated Fair Value (DCF)
$169.07
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-6.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
9.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 9.0% | $926.02M | $849.56M |
| 2 | 7.4% | $994.60M | $837.13M |
| 3 | 5.8% | $1.05B | $812.33M |
| 4 | 4.1% | $1.10B | $776.07M |
| 5 | 2.5% | $1.12B | $729.79M |
Base FCF (last actual year)
$849.25M
Terminal Value
$17.71B
Present Value of Terminal Value
$11.51B
Enterprise Value
$15.51B
Net Debt
$4.61B
Equity Value
$10.90B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$112.87
Tangible Book Value per Share (Tangible NAV)
$49.79
Sentiment based on basic keywords (not AI) — 5 positive, 11 neutral, 4 negative out of the last 20 articles.
SeekingAlpha · 15.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 9.9.2026
Investor's Business Daily · 9.9.2026
SeekingAlpha · 8.9.2026
MT Newswires · 1.9.2026
Yahoo · 28.8.2026
Zacks · 28.8.2026
ChartMill · 27.8.2026
SeekingAlpha · 27.8.2026
Yahoo · 26.8.2026
Zacks · 26.8.2026
Yahoo · 26.8.2026
Simply Wall St. · 26.8.2026
Yahoo · 25.8.2026
PR Newswire · 25.8.2026
Yahoo · 25.8.2026
Barchart · 25.8.2026
CNBC · 21.8.2026
Yahoo · 20.8.2026
Universal Health Services (UHS) currently has a StockIQ AI score of 60/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
UHS currently scores 60/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, UHS's estimated fair value is $169.07, which is 6.7% below the current price of $181.21. This is one valuation model among several signals in the fair-value category, not a price target.
UHS's technical score is 69/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 37.3%; Net income growth: 30.4%; Return on equity (ROE): 20.5% — strong.
Based on the real signals StockIQ computed: Operating margin is eroding over time; Calmar: 0.29 (3y annualized return 12.4% / max drawdown 42.2%); Free cash flow growth: -24.4%.
Yes — UHS has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| MILLER ALAN B | Other Transaction | 27.5.2026 | 14,163 | -14,163 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 14,163 | +14,163 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 25,495 | +25,495 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 25,495 | +25,495 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 14,163 | -14,163 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 9,418 | +9,418 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 9,418 | -9,418 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 9,418 | +9,418 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 14,163 | +14,163 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 25,495 | -25,495 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 14,163 | +14,163 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 13,963 | +13,963 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 13,963 | -13,963 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 50,990 | +50,990 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 50,990 | -50,990 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 9,418 | -9,418 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 25,495 | -25,495 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 14,163 | -14,163 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 1,810,129 | +13,963 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 1,819,547 | +9,418 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 0 | -9,418 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 1,828,965 | +9,418 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 1,843,128 | +14,163 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 1,857,291 | +14,163 | — |
| MILLER ALAN B | Other Transaction | 27.5.2026 | 10,132 | -14,163 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,575,023 shares short as of 2026-08-31 · vs. 2,999,451 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
68.7% of trading volume this week was short selling, vs. 76.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology